Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces Aranesp analysis

Amgen announces Aranesp analysis

27th September 2007

Amgen has today announced the analysis of the Aranesp Danish Head and Neck Cancer (Dahanca) 10 study presented at the 14th European Cancer Conference (Ecco) in Barcelona, Spain.

The Dahanca study group detailed how the research was part of a continuing Aranesp pharmacovigilance programme, intended to evaluate the experimental circumstance of whether using Aranesp to maintain hemoglobin (Hb) levels between 14.0 to 15.5 g/dL resulted in better outcomes for patients with squamous cell carcinoma of the head and neck (HNSCC).

It was hoped that by allowing more oxygen to reach the tumour it would make it more sensitive to radiotherapy.

The study found that patients with HNSCC and who were treated with Aranesp had extensively poorer tumour control after radiotherapy though there were no significant differences in overall survival.

Willard Dere, Amgen senior vice president, outlined that while Arenesp had been approved to treat anaemic patients receiving chemotherapy, it had no such approval for use in the clinical situation investigated in this trial.

“Amgen continues to recommend the use of Aranesp to treat patients with anaemia only in accordance with its approved product labelling, and remains committed to providing patients and their physicians with the most accurate information to make informed treatment decisions,” he said.

Earlier this month, Amgen presented the results of a phase III clinical study of Aranesp to the World Conference on Lung Cancer in Seoul.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.